SignPost Cancer Dx creates BreastDefense, a new class of precise diagnostic tests for breast cancer, based on molecular medicine.
SignPost Cancer Dx has raised $250K in total funding. The most recent round was Seed. The last funding was announced in January 2023.
SignPost Cancer Dx's investors include Newchip Accelerator.
SignPost Cancer Dx is headquartered in Kingston, Canada.
SignPost Cancer Dx creates BreastDefense, a new class of precise diagnostic tests for breast cancer, based on molecular medicine.
SignPost Cancer Dx is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SignPost Cancer Dx — Funding & Investors." VCBacked, January 30, 2023, https://www.vcbacked.co/company/signpost-cancer-dx. Accessed July 27, 2026.
VCBacked. (2023). SignPost Cancer Dx — Funding & Investors. Retrieved July 27, 2026, from https://www.vcbacked.co/company/signpost-cancer-dx
{{cite web |title=SignPost Cancer Dx — Funding & Investors |url=https://www.vcbacked.co/company/signpost-cancer-dx |website=VCBacked |access-date=July 27, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated